Merck & Co., Inc. (NYSE:MRK) Director Leslie A. Brun sold 3,052 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $77.22, for a total value of $235,675.44. Following the sale, the director now directly owns 5,000 shares in the company, valued at $386,100. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of MRK traded down $0.81 during mid-day trading on Monday, reaching $76.71. The company had a trading volume of 12,962,200 shares, compared to its average volume of 13,190,743. The company has a quick ratio of 1.15, a current ratio of 1.44 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $80.19. The stock has a market cap of $209.01 billion, a P/E ratio of 17.68, a P/E/G ratio of 2.05 and a beta of 0.62.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, February 1st. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.01. Merck & Co., Inc. had a return on equity of 35.10% and a net margin of 14.71%. The firm had revenue of $11 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the previous year, the firm posted $0.98 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. On average, equities analysts anticipate that Merck & Co., Inc. will post 4.65 EPS for the current year.
Merck & Co., Inc. announced that its Board of Directors has approved a share repurchase program on Thursday, October 25th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 5.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a $0.55 dividend. The ex-dividend date is Thursday, March 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.87%. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.
MRK has been the topic of several research reports. BMO Capital Markets cut Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective on the stock. in a research report on Wednesday, January 23rd. SunTrust Banks lifted their price objective on Merck & Co., Inc. from $77.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, October 29th. ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Morgan Stanley set a $81.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, December 20th. Finally, Wolfe Research initiated coverage on Merck & Co., Inc. in a research report on Tuesday, October 23rd. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $73.15.
Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its stake in Merck & Co., Inc. by 3.2% during the 2nd quarter. FMR LLC now owns 5,037,262 shares of the company’s stock valued at $305,762,000 after buying an additional 157,592 shares during the last quarter. Boulegeris Investments Inc. grew its holdings in shares of Merck & Co., Inc. by 18.0% during the second quarter. Boulegeris Investments Inc. now owns 12,505 shares of the company’s stock worth $759,000 after buying an additional 1,905 shares in the last quarter. BlueMountain Capital Management LLC grew its holdings in shares of Merck & Co., Inc. by 3,029.9% during the second quarter. BlueMountain Capital Management LLC now owns 59,469 shares of the company’s stock worth $3,610,000 after buying an additional 57,569 shares in the last quarter. Oregon Public Employees Retirement Fund purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth about $17,887,000. Finally, Baird Financial Group Inc. grew its holdings in shares of Merck & Co., Inc. by 5.5% during the second quarter. Baird Financial Group Inc. now owns 1,540,958 shares of the company’s stock worth $93,536,000 after buying an additional 80,806 shares in the last quarter. 74.29% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Zolmax and is owned by of Zolmax. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://zolmax.com/investing/leslie-a-brun-sells-3052-shares-of-merck-co-inc-mrk-stock/2892456.html.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Featured Article: What are retained earnings?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.